Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Growth Inhibitiory Effect of New Pyrrolo[1,2-${\alpha}$]benzimidazole Derivatives on Human Gastric Cancer Cells

  • Kim, Soo-Kie (Department of Microbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Ahn, Chan-Mug (Department of Basic Sciences, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Choi, Sun-Ju (Department of Micorbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Park, Yoon-Sun (Department of Microbiology, College of Medicine, Kwangdong University) ;
  • Cho, Hyung-Chul (Department of Micorbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University) ;
  • Koh, Choon-Myung (Department of Micorbiology, Institute of Basic Medical Sciences, Wonju College of Medicine, Yonsei University)
  • Published : 1997.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

In the course of screening synthetic compounds to inhibit tumor cell growth, pyrrolo[1,2-.alpha.] benzimidazole (PBI), an intermediate of azamitosene, was found to inhibit a proliferation of gastric cancer cell lines. Despite a potential cytotoxic activity against solid tumor cells as opposed to that against rapidly-doubled leukemic cells, there has been no report on the inhibition of gastric cancer cell line by PBI and its' derivatives. The present experiment was designed to determine if PBI derivatives can effectively inhibit the cellular proliferation of gastric cancer cells by using in vitro as well as in vivo chemosensitivity system (MTT assay, clonogenic assay and human tumor xenografted assay). Of the tested PBI derivatives, PBI (18) and PBI (20), displayed the effective growth inhibition of cultured gastric cancer cells or even in the xenografted nude mouse model.

Keywords

References

  1. Arch. Pharm. Res. v.19 Synthesis and in vitro antitumor activity of isoazamitosene and isoiminoazamitosene derivatives Ahn,C.M.;Kim,S.K.
  2. Cancer Res. v.47 Evaluation of a tetrazolium-based semiautomated colorimetric assay; assessment of radiosenstivity Carmichael,J.;deGraff,W.G.;Gazdar,A.F.;Minna,J.D.;Mitchel,J.B.
  3. Proc. Am. Soc. Clin. Oncol. v.14 Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C and tegafur plus uracil, strating first week fater surgery, for gastric adenocarcinoma Carrato,A.;Diaz-Rubio,E.;Medrano,J.
  4. J. Kor. Cancer Assoc. v.29 In vitro growth inhibition of mitosene analogues on human ovarian cancer cell lines Cha,D.S.;Kim,S.K.;Ahn,C.M.;Choi,S.J.;Park,Y.S.;Han,S.W.
  5. J. Org. Chem. v.55 Synthesis and Physical studies of azamitosenes and iminoazamitosene reductive alkylating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry Islam,I.;Skibi,E.B.
  6. J. Med. Chem. v.34 Structure-activity studies of antitumor agents based on pyrrolo[1,2-α] benzimidazoles:new reductive alkylation DNA cleaving agents Islam,I.;Skibo,E.B.
  7. J. Med. Chem. v.26 Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7 Iyengar,B.S.;Sami,S.M.;Remers,W.A.;Bradner,W.T.;Schurig,J.E.
  8. Semin. Oncol. v.23 no.3 Adjuvant and neoadjuvant therapy for gastric caccer Kelson,D.P.
  9. Biochem. Pharmacol. v.29 The hypoxic tumor cell: a target for selective cancer chemotherapy Kennedy,K.A.;Teicher,B.A.;Rockwell,I.S.;Sartorelli,A.C.
  10. Adv. Enz. Reg. v.23 Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C. Keyes,S.R.;Heimbrook,D.C.;Fracasso,P.M.;Rockwell,S.;Sligar,S.G.;Sartorelli,A.C.
  11. Arch. Pharm. Res. v.19 In vitro chemosensitivity test of SK-302B on human colon carcinoma cell lines Kim,S.K.;Ahn,C.M.;Kim,T.U.;Choi,S.J.;Park,Y.S.;Shin,W.S.;Koh,C.M.
  12. J. Kor. Caccer Assoc. v.21 Five years report for cancer register program in the republic of Korea (1982.7.1-1989. 6.30) Ministry of Health and Social Affairs
  13. Med. Res. Rev. v.1 Naturally occurring quinones as potential bioreductive alkylating agents Moore,H.W.;Czerniak,P.
  14. Eur. J. Cancer. v.30A Efficicacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor anaysis Rougier,P.H.;Ducreux,M.;Mahjoubi,M.
  15. N. Engl. J. Med. v.298 Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs Salmon,S.E.;Hamberger,A.W.;Soehnlen,B.;Durie,B.G.M.;Alberts,D.S.;Moon,T.E.
  16. J. Med. Chem. v.7 Mitomycin C analogues with aryl substitutions on the 7-amino group Sami,S.M.;Iyengar,B.S.;Tarnow,S.E.;Remer,W.A.;Bradner,W.T.;Schurig,J.E.
  17. Stem Cell v.1 Measurement of tumor colony growth and drug sensitivity in soft agarose culture using a radiosisotope method Shoemaker,R.H.;Igel,H.J.;McLachlan,S.S.;Harfiel,J.L.
  18. J. Med. Chem. v.36 Pyrrolo[1,2-α]benzimidazole-based aziridinyl quinones. a new class of DNA cleaving agent exhibiting G and A base specificity Skibo,E.B.;Schulz,W.G.